Company · Investors

Measuring the eye
between visits.

Eyevariant turns a phone camera or webcam into a daily, clinically grounded monitor of the optic nerve and visual function, and a lens that adapts every screen to the eyes looking at it.

The problem, in numbers

Vision loss from optic nerve disease is silent, permanent and measured only a few times a year.

76M → 112MPeople with glaucoma, 2020 to 2040Tham et al., Ophthalmology 2014
~50%Of people with glaucoma don't know they have itWidely reported in high-income countries; higher elsewhere
2.2BPeople with a near or distance vision impairmentWHO World Report on Vision, 2019
3–6 moTypical gap between glaucoma monitoring visitsDamage in between goes unseen

Investment thesis

One real-time engine, two products, and a clinical data asset that compounds with every measurement.

01 · Insight

The pupil is a biomarker hiding in plain sight

Chromatic pupillometry reflects retinal ganglion cell function, the cells glaucoma destroys. Until now it required clinic hardware; modern phones can deliver the stimulus and the measurement.

02 · Why now

The hardware is already in every pocket

  • 60 fps cameras and depth sensors on mainstream phones
  • On-device machine learning fast enough for per-frame analysis
  • Remote monitoring now reimbursed in some markets
  • Neuroprotective therapies entering trials need sensitive endpoints
03 · Products

Monitoring and daily use, on one engine

  • Eyevariant: optic nerve and retinal function monitoring for patients and clinics
  • Adaptive Gaze Lens: prescription-aware magnification for everyday screens
  • Usage data from the Lens enriches the clinical record
04 · Model (planned)

Several paths to revenue

  • Clinic subscription per monitored patient
  • Consumer subscription for the Adaptive Gaze Lens
  • Research partnerships: objective endpoints for clinical trials
  • Remote monitoring reimbursement where available

Roadmap

Engineering milestones gated by clinical validation, on a medical device quality path from day one.

PHASE 0

Research

Science, architecture and product design complete

PHASE 1

Gaze Lens

Adaptive magnifier on Windows, built on the shared engine

PHASE 2

Eyevariant

Pupil test, biomarkers and clinician report on Windows and Android

PHASE 3

Strain

Passive habit and eye-strain monitoring

PHASE 4

Android Lens

Gaze Lens on Android, both products linked; macOS and iPhone after

PHASE 5

Clinical

Validation study and regulatory submission

Investor materials

Request the deck.

We share our investor deck, technical overview and validation plan with qualified investors on request.

This page is for information only. It is not an offer to sell, or a solicitation of an offer to buy, any securities. Any offering will be made only through definitive documents and in accordance with applicable law.